SAFETY
AND
ANTIGENICITY
OF
INACTIVATED
INFLUENZA
VIRUS
VACCINES
IN
CHILDREN
TRIALS
WITH
MONOVALENT
AND
BIVALENT
ANEW
JERSEY76
HSWN1
AND
AVICTORIA75
VIRUS
VACCINES
IN
WASHINGTON
DC
SAFETY
AND
ANTIGENICITY
OF
MONOVALENT
AND
BIVALENT
ANEW
JERSEYNJ76
HSSN1
AND
AVICTORIA75
INACTIVATED
INFLUENZA
VIRUS
VACCINES
WERE
STUDIED
IN
125
CHILDREN
AGED
THREE
TO
18
YEARS
IN
RECRUITMENT
FAMILIES
WHO
KNEW
THE
STUDY
TEAM
WHO
WERE
PROFESSIONALLY
INVOLVED
ANDOR
WHO
WERE
UNDER
CLOSE
CONTINUING
CARE
WERE
MORE
LIKELY
TO
VOLUNTEER
FOR
SUCH
STUDIES
THAN
THOSE
WHO
WERE
UNFAMILIAR
WITH
THE
TEAM
OR
INSTITUTION
ANTIBODY
RESPONSES
AND
SYSTEMIC
REACTIONS
OCCURRED
MORE
OFTEN
AFTER
ADMINISTRATION
OF
INACTIVATED
WHOLEVIRUS
VACCINE
THAN
AFTER
SPLITVIRUS
VACCINE
SIGNIFICANT
TITERS
GREATER
THAN
OR
EQUAL
TO
140
OF
HEMAGGLUTINATIONINHIBITING
ANTIBODY
TO
ANJ76
VIRUS
OCCURRED
IN
95
OF
NORMAL
CHILDREN
THREE
TO
18
YEARS
OF
AGE
WHO
RECEIVED
TWO
DOSES
OF
THE
SAME
VACCINE
WHOLE
OR
SPLIT
HOWEVER
INSUFFICIENT
NUMBERS
OF
CHILDREN
ACHIEVED
A
REASONABLE
ANTIBODY
TITER
GREATER
THAN
OR
EQUAL
TO
140
AFTER
ONE
DOSE
OF
VACCINE
CT
1
VASILYEVA
RI
ZH
MIKROBIO
EPIDEMIO
IMMUNOBI
1982
96
982
